Find disease awareness content and relevant supporting materials
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adverse cardiovascular events.
American College of Cardiology recommends Jardiance as the preferred SGLT2 inhibitor for reduction of the risk of cardiovascular death and CV disease in adults with type 2 diabetes.- Eli Lilly.
A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred...